Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 The bet inhibitor JQ1 augments the antitumor efficacy of gemcitabine in preclinical models of pancreatic cancerCancers.  13. 2021
2019 Tyrosyl-DNA phosphodiesterase I N-Terminal domain modifications and interactions regulate cellular functionGenes.  10. 2019
2019 The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsEBioMedicine.  44:419-430. 2019
2019 Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts 2019
2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancerCancer Letters.  436:75-86. 2018
2018 JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinomaMolecular Cancer Therapeutics.  17:107-118. 2018
2018 Sphingolipid metabolism and drug resistance in ovarian cancer 2018
2017 DNA topoisomerase-targeting chemotherapeutics: what’s new?Cancer Chemotherapy and Pharmacology.  80. 2017
2016 Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxinOncotarget.  7:86660-86674. 2016
2016 Tyrosyl-DNA Phosphodiesterase I a critical survival factor for neuronal development and homeostasis.J Neurol Neuromedicine.  1:25-29. 2016
2015 ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actininOncogene.  34:1553-1562. 2015
2015 Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavageJournal of Biological Chemistry.  290:6203-6214. 2015
2014 Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic targetDrug Metabolism Reviews.  46:494-507. 2014
2012 Erratum: Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: A member of the phospholipase D superfamily (Journal of Molecular Biology (2012) 415:4 (741-758))Journal of Molecular Biology.  416:725. 2012
2012 Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: A member of the phospholipase D superfamilyJournal of Molecular Biology.  415:741-758. 2012
2007 Mutation of a Conserved Active Site Residue Converts Tyrosyl-DNA Phosphodiesterase I into a DNA Topoisomerase I-dependent PoisonJournal of Molecular Biology.  372:1070-1081. 2007
2007 Structure of a SUMO-binding-motif Mimic Bound to Smt3p-Ubc9p: Conservation of a Non-covalent Ubiquitin-like Protein-E2 Complex as a Platform for Selective Interactions within a SUMO PathwayJournal of Molecular Biology.  369:619-630. 2007
2006 Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stressMolecular and Cellular Biology.  26:4958-4969. 2006
2005 Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damageJournal of Biological Chemistry.  280:23566-23575. 2005
2004 Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecinJournal of Biological Chemistry.  279:54502-54509. 2004
2004 Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell linesCancer Chemotherapy and Pharmacology.  54:71-78. 2004
2004 Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisonsMolecular Cancer Therapeutics.  3:393-402. 2004
2003 In vitro pharmacokinetic study of the novel anticancer agent E7070: Red blood cell and plasma protein binding in human blood 2003
2003 DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatinBiochemical Pharmacology.  65:275-282. 2003
2002 Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study 2002
2002 DNA-based drug interactions of cisplatinCancer Treatment Reviews.  28:291-303. 2002
2001 Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918Clinical Cancer Research.  7:935-941. 2001
1999 32P-postlabeling assay for the quantification of the major platinum- DNA adductsAnalytical Biochemistry.  275:30-38. 1999
1999 Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell lineCancer Research.  59:4559-4563. 1999
1998 Effects of c-MYC oncogene modulation on differentiation of human small cell lung carcinoma cell lines 1998
1998 Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines. 1998
1997 Effects of an inducible anti-sense c-myc gene transfer in a drug- resistant human small-cell-lung-carcinoma cell lineInternational Journal of Cancer.  73:544-550. 1997
1997 Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line.International Journal of Cancer.  73:544-550. 1997
1996 Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines 1996
1996 Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. 1996
1994 Cis‐acting elements reinforcing the activity of the estrogen‐response element in the very‐low‐density apolipoprotein II gene promoter 1994

Chapter

Year Title Altmetric
2015 The ubiquitin/proteasome pathway in neoplasia.  473-480. 2015

Teaching Activities

  • GBS703 - Res Analysis & Presentation (Fall Term 2013)
  • GBS703 - Res Analysis & Presentation (Fall Term 2017)
  • GBS703 - Res Analysis & Presentation (Spring Term 2018)
  • GBS747 - Special Topics Biomed Sci II (Fall Term 2012)
  • GBS753 - Pharm & Molec Med (Spring Term 2015)
  • GBS753 - Pharm & Molec Med (Spring Term 2016)
  • GBS753 - Pharm & Molec Med (Spring Term 2017)
  • GBS753 - Pharm & Molec Med (Spring Term 2018)
  • GBS753 - Pharm Tox & Molec Med (Spring Term 2020)
  • GBS753 - Pharm Tox & Molec Med (Spring Term 2021)
  • GBS753 - Pharmacology & Molec Med (Spring Term 2019)
  • GBSC742 - Student Theme Meeting Course (Fall Term 2018)
  • GBSC742 - Student Theme Meeting Course (Fall Term 2019)
  • GBSC742 - Student Theme Meeting Course (Fall Term 2020)
  • GBSC742 - Student Theme Meeting Course (Fall Term 2021)
  • GBSC742 - Student Theme Meeting Course (Spring Term 2019)
  • GBSC742 - Student Theme Meeting Course (Spring Term 2020)
  • GBSC742 - Student Theme Meeting Course (Spring Term 2021)
  • PAT704 - Pathology Res: Data Analysis (Fall Term 2011)
  • PHR790 - Advanced Pharmacology Seminar (Fall Term 2010)
  • PHR790 - Advanced Pharmacology Seminar (Fall Term 2011)
  • PHR790 - Advanced Pharmacology Seminar (Fall Term 2012)
  • PHR790 - Advanced Pharmacology Seminar (Fall Term 2013)
  • PHR790 - Advanced Pharmacology Seminar (Fall Term 2014)
  • PHR790 - Advanced Pharmacology Seminar (Spring Term 2011)
  • PHR790 - Advanced Pharmacology Seminar (Spring Term 2012)
  • PHR790 - Advanced Pharmacology Seminar (Spring Term 2013)
  • TOX795 - Advanced Toxicology Seminar (Spring Term 2014)
  • Education And Training

  • Doctorate Level Degree in Oncology and Cancer Biology, University of Groningen 1997
  • Full Name

  • Robert van Waardenburg